CanSino Biologics' combination vaccine receives China trial approval

CanSino Biologics Inc. (HKEX: 6185) announced that its DTcP-Hib-MCV4 combined vaccine has been granted clinical trial approval by the National Medical Products Administration of the People's Republic of China. This approval allows CanSino to initiate clinical trials for the vaccine, which combines protection against diphtheria, tetanus, pertussis, Haemophilus Influenzae Type b, and Meningococcal diseases. As a component of this vaccine, the company notes that its Menhycia® MCV4 vaccine is already approved and commercialized in China. The DTcP Infant vaccine is under the Phase III clinical trial, and the Hib Vaccine is under the Phase I clinical trial. The company intends to leverage the data from these trials to develop the DTcP-Hib-MCV4 combined vaccine to meet market demand and gain a competitive edge. Shareholders and potential investors are advised to exercise caution when dealing in the company's shares.